MedPath

ICG and Blue Dye Guided Sentinel Lymph Node Biopsy in Patients Underwent Neoadjuvant Therapy

Conditions
Breast Neoplasms
Interventions
Procedure: ICG+Methylene Blue
Registration Number
NCT02869815
Lead Sponsor
Peking University People's Hospital
Brief Summary

The value of sentinel lymph node biopsy (SLNB) in patients underwent neoadjuvant chemotherapy is controversial. Lower detection rate and higher false negative rate are the main problem. The purpose of this study is to determine the detection rate and the false negative rate of SLNB by indocyanine green (ICG) in addition to blue dye (methylene blue) after neoadjuvant chemotherapy in patients with large or locally advanced breast cancer. This is a single arm clinical trial.

Detailed Description

Patients indicated for neoadjuvant therapy would be recruited in this study. During the surgery, SLNB using the dual tracing method would be applied before axillary clearance. After the surgery, histological results of the SLN and non-SLN would be analysed.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
150
Inclusion Criteria
  • Patients indicated for neoadjuvant therapy
  • Have complete evaluation of the axillary status
  • Planned for axillary clearance after neoadjuvant therapy
Exclusion Criteria
  • Sensitive to Iodine
  • Inflammatory disease
  • Patient's refusal to join the trial

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ICG+Methylene BlueICG+Methylene BlueICG+Methylene Blue: Sentinel Lymph Node (SLN) identification and resection using dual tracer technique with the sub-areolar injection of ICG+Blue dye, before surgery.
Primary Outcome Measures
NameTimeMethod
Detection rate of SLNImmediate

The number of successful SLNB / total number of SLNB

Secondary Outcome Measures
NameTimeMethod
False negative rate of SLNB1 week after the surgery

The number of patients with positive SLN / the number of patients with positive node

Adverse effectHalf a year after the surgery

Prophylaxis reaction, skin complication

Trial Locations

Locations (1)

Breast Center, Peking University People's Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath